Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363051 · ClinicalTrials.gov registry record · Phase 2
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00363051 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 160 participants.
The verdict
NCT00363051, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the efficacy and safety of everolimus in the treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic chemotherapy. All patients were treated with everolimus until either tumor progression was documented using a standard criteria that measures tumor size called Response Evaluation Criteria in Solid tumors (RECIST), or until unacceptable toxicity occurred, or until the patient or investigator requested discontinuation of treatment.
Interventions
- DRUG Octreotide Depot
- DRUG Everolimus 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2006-06 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363051
The ClinicalTrials.gov registry entry for NCT00363051 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Octreotide Depot is the first listed.
NCT00363051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00363051 about?
NCT00363051 is a clinical study titled "Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy". The purpose of this study was to assess the efficacy and safety of everolimus in the treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic chemotherapy. All patients were treated with everolimus until either tumor progression was documented using a standard criteria...
What is the current status of trial NCT00363051?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2006-06. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00363051?
The interventions under investigation include: Octreotide Depot (DRUG), Everolimus 10 mg (DRUG).
Who is sponsoring clinical trial NCT00363051?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.